# Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease

> **NCT07187167** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Rosai-Dorfman Disease

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07187167
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-12
- **Primary completion:** 2027-04-12
- **Final completion:** 2027-04-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187167, "Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07187167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*